Phase 1

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

• This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.

Status: Recruiting

Trial Details

Phase 1b

A Phase 1b Study of SDX-7320 in Combination with Approved Anti-Cancer Agents to Assess Safety in Patients with Metastatic Breast Cancer

• This is a multicenter Phase 1b study to assess the safety, tolerability and efficacy of subcutaneously administered SDX-7320 in combination with the standard dose and schedule of approved anti-cancer treatments in postmenopausal women with advanced HR+/HER2- metastatic breast cancer and suspected metabolic dysfunction who have progressed after an initial treatment regimen of hormone therapy with or without a targeted therapy.
• Other selected, advanced, metabolically-sensitive solid tumor types will be considered for separate treatment arms in both men and women.

Status: Planning to start in late 2017